A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium Objectives 1st extension: 1. To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. 2. To assess safet...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of safety and efficacy of different doses of the study drug, MK-0854/Losartan Potassium, in pediatric patients with high blood pressure assigned to different groups randomly. Treatment is known to doctor and patient (1) To define a dose-response relationship for losartan in hypertensive children aged 6 months to 6 years, after a 21-day open-label treatment period (response assessed by change from baseline in mean...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Pembrolizumab in Subjects with Advanced Recurrent Ovarian Cancer (1) To evaluate clinical anti-tumor activity of pembrolizumab monotherapy based on overall response rate (ORR) as assessed by CIV per RECIST 1.1 in Cohort A-All Comer group (2) To evaluate clinical...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Women with Osteoporosis For Base Study: To assess the effect of L-001037536 3 mg weekly, 10 mg weekly, 25 mg weekly, and 50 mg weekly on lumbar spine BMD compared to placebo over 12 months. For 24 Months Extension: To ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder (OAB) 1. To assess the long-term safety and tolerability of treatment with MK-4618 compared to tolterodine ER. 2. To assess the long-term safety profile of MK-4618 dosed concomitantly with tolterodine ER...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate AD (EPOCH) Part I (main cohort) - Primary Trial Objectives: 1. To assess the efficacy of two doses of MK-8931 on cognition in subjects with mild to moderate AD. 2. To assess the efficacy of two doses of MK-893...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE ESTUDIO PARA EVALUAR LOS SUCESOS CARDIOVASCULARES TRAS EL TRATAMIENTO CON ERTUGLIFLOZINA EN PACIENTES CON DIABETES MELLITUS TIPO 2 Y ENFERMEDAD CARDIOVASCULAR ESTABILIZADA Objective: To demonstrate the non inferiority of ertugliflozin compared with a non ertugliflozin comparator group on the time to first occurrence of any of the components of the composite endpoint of ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized Sitagliptin Withdrawal Study In subjects with T2DM with inadequate glycemic control on metformin and sitagliptin, who initiate and titrate insulin glargine (LANTUS®), to assess the effect of continuing sitagliptin relative to wit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042) 1) To compare the overall survival (OS) in subjects with PD-L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to standard of care (SOC) chemotherapies. 2) To co...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Adult Lamivudine and Tenofovir Biocomparison Study for Pediatric Fixed Dose Combination Formulation To evaluate the comparative bioavailability of: 1.lamivudine 300mg: a. adult marketed tablets to the investigational oral pediatric uncoated/coated granules-fasted conditions b.investigational oral...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune